Eric Lander 'bullied and demeaned' staff at White House science office — investigation

Amber Tong

Senior Editor

A recent White House investigation concluded that Eric Lander, President Biden’s top science advisor, bullied and demeaned his subordinates, Politico reported.

The news dropped just hours after Politico reported that Lander, the famed but often controversial geneticist who served as founding director of the Broad Institute before getting tapped to lead the White House’s Office of Science and Technology Policy, emailed all his staff to apologize for speaking to colleagues in a “disrespectful and demeaning way.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Eric Lander 'bullied and demeaned' staff at White House science office — investigation

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

FDA unveils new rare disease pilot program to increase agency-sponsor communications

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

Madrigal raises $500M for NASH drug launch, discloses cyberattack

CMIC: Japan’s first and largest CRO continues 30-year evolution to help global sponsors navigate the complex local ...

Er­ic Lan­der 'bul­lied and de­meaned' staff at White House sci­ence of­fice — in­ves­ti­ga­tion

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

FDA rolls out long-await­ed pro­pos­al to over­haul di­ag­nos­tics reg­u­la­tion

FDA un­veils new rare dis­ease pi­lot pro­gram to in­crease agency-spon­sor com­mu­ni­ca­tions

In the race to get type 1 pa­tients off in­sulin, fo­cus turns to cell trans­plants and in­sulin-pro­duc­ing stem cells

De­spite a sum­mer of block­buster rounds, biotech fund­ing is on track to lev­el off at pre-pan­dem­ic norms

Madri­gal rais­es $500M for NASH drug launch, dis­clos­es cy­ber­at­tack

CMIC: Japan’s first and largest CRO con­tin­ues 30-year evo­lu­tion to help glob­al spon­sors nav­i­gate the com­plex lo­cal ...

Eric Lander 'bullied and demeaned' staff at White House science office — investigation

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

FDA unveils new rare disease pilot program to increase agency-sponsor communications

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

Madrigal raises $500M for NASH drug launch, discloses cyberattack

CMIC: Japan’s first and largest CRO continues 30-year evolution to help global sponsors navigate the complex local ...